ArticleBMC musculoskeletal disorders2025
Correlation of serum pentraxin 3 expression with disease severity and its prognostic value in postmenopausal osteoporosis.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivePentraxin 3 (PTX3) is an acute-phase protein of the pentraxin family, primarily secreted by immune cells and endothelial cells. This study analyzed its correlation with the severity of postmenopausal osteoporosis (PMOP) and its prognostic value.
methodsPostmenopausal women (n = 405) were retrospectively selected and arranged into normal bone mineral density (BMD), osteopenia, and PMOP groups. Baseline data and follow-up records were analyzed. Serum PTX3 were quantified, and its correlations with Oswestry Disability Index (ODI), Visual Analogue Scale (VAS) score, BMD, and bone turnover markers (BTMs) were analyzed. The independent risk factors for fractures in PMOP patients were screened. The prediction of PTX3 for fractures was evaluated, and its effects, together with BMD, on fracture risk were assessed.
resultsPMOP patients showed reduced BMD and serum 25-hydroxyvitamin D levels and increased BTM and PTX3 levels. Serum PTX3 showed positive correlations with ODI, VAS scores, and BTM levels, but negative correlations with BMD. PMOP patients experiencing fractures exhibited markedly higher PTX3 levels than non-fracture patients. Multivariate analysis identified PTX3 as an independent risk factors for fractures in PMOP patients, while elevated BMD (lumbar spine, femur neck, and hip joint) as protective factors. PTX3 demonstrated superior predictive accuracy for fracture risk in PMOP patients (area-under-the-curve [AUC]: 0.874) over β-CTX (AUC = 0.689), PINP (AUC = 0.811), OC (AUC = 0.831), lumbar spine BMD (AUC = 0.791), femoral neck BMD (AUC = 0.793), and hip joint BMD (AUC = 0.799), with no statistically significant differences (all p > 0.05). Low BMD and high PTX3 levels elevated fracture risk in PMOP patients.
conclusionSerum PTX3 levels are correlated with BMD, BTMs, and symptom severity, and can assist in predicting fractures in PMOP patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.